Patient is currently receiving any of the following medications and cannot be discontinued  days prior to treatment start:\r\n* Known strong inducers or inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA)/cytochrome P, family , subfamily A, polypeptide  (), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* That have a known risk to prolong the QT interval or induce Torsades de Pointes\r\n* Herbal preparations/medications, dietary supplements
Patients must be willing and able to avoid consuming food and beverages containing grapefruit, star fruit or Seville oranges while on ibrutinib study therapy
Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within  days prior to starting venetoclax
Currently receiving any of the following medications and cannot be discontinued  days prior to starting the study\r\n* Herbal supplements including grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges or products containing the juice of each; orange juice is allowed\r\n* Known strong inducers or inhibitors of CYPA/ including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges\r\n* Medications known to have a narrow therapeutic window and are predominantly metabolized through CYPA
In general, the use of any concomitant medication deemed necessary for the care of the patient is permitted in this study, except as specifically prohibited below; combination administration of study drugs could result in drug-drug interactions (DDI) that could potentially lead to reduced activity or enhanced toxicity of the concomitant medication and/or ribociclib; patient is currently receiving any of the following medications and cannot discontinue use within  days prior to starting study drug:\r\n* Known strong inducers or inhibitors of cytochrome P, family , subfamily A, polypeptide / (CYPA/), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges that have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* Herbal preparations/medications\r\n* Dietary supplements
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to treatment:\r\n* Known strong inducers or inhibitors of CYPA/ or bile salt pump efflux, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges;\r\n* That have a known risk to prolong the QT interval or induce torsades de pointes;\r\n* Herbal preparations/medications, dietary supplements;\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYPA/
Patient receiving any of the following medications within  days of day  of study treatment:\r\n* Known strong inducers or inhibitors of cytochrome P, family , subfamily A, polypeptide / (CYPA/), including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* That have a known risk to prolong the QT interval or induce torsades de pointes\r\n* Herbal preparations/medications
In addition, grapefruit, grapefruit juice, seville oranges and star fruit should be avoided, as they inhibits CYPA
Consumption of grapefruits, grapefruit products, Seville oranges (including marmalade that contains Seville oranges), or star fruit within  days prior to the first dose of venetoclax.
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYPA/, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* Herbal preparations/medications, dietary supplements; acceptable supplements include multivitamins, vitamin D and calcium\r\n* Angiotensin-converting enzyme (ACE) inhibitor therapy
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYPA/, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges, that have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* Herbal preparations/medications, dietary supplements
Received the following agents within  days prior to the first dose of venetoclax:\r\n* Steroid therapy for anti-neoplastic intent \r\n* Strong and moderate CYPA inhibitors \r\n* Strong and moderate CYPA inducers\r\n* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within  days prior to the first dose of venetoclax
Subject has consumed grapefruit, grapefruit products, seville oranges (including marmalade containing seville oranges) or star fruit within  days prior to the initiation of study treatment
Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within  days prior to the initiation of study treatment.
Patients requiring the following agents within  days prior to the first dose of venetoclax are excluded:\r\n* Steroid therapy for anti-neoplastic intent\r\n* Strong CYPA inhibitors\r\n* Strong CYPA inducers\r\n* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within  days prior to the first dose of venetoclax\r\n* NOTE: moderate CYPA inhibitors and inducers should be used with caution and an alternative medication used, whenever possible
Consuming grapefruit, grapefruit products, Seville oranges, or star fruit within  days of starting venetoclax
Consumption of grapefruit, grapefruit hybrids, pummelos, star-fruit, Seville oranges or products containing the juice of each within  days prior to study registration.
Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within  days prior to the initiation of study treatment.
Currently receiving any of the following that cannot be discontinued at least  days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYPA/, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* Medications with a narrow therapeutic window that are predominantly metabolized through CYPA/\r\n* Herbal supplements, such as St. Johns wort; the use of marijuana or its derivatives is allowed in States with statutes permitting the use of recreational or medical marijuana
Received the following agents within  days prior to the first dose of venetoclax:\r\n* Strong and moderate CYPA inhibitors\r\n* Strong and moderate CYPA inducers\r\n* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within  days prior to the first dose of venetoclax
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYPA/, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* Herbal preparations/medications, dietary supplements
Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within  days of starting study drugs
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug\r\n* Known strong inducers or inhibitors of cytochrome P, family , subfamily A, polypeptide / (CYPA/), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* Herbal preparations/medications, dietary supplements
Grapefruit and grapefruit juice (CYPA inhibitor), Seville oranges and star fruit consumption is not permitted during the study
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug:\r\n* Known strong inducers or inhibitors of cytochrome P family  subfamily A member / (CYPA/), including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* That have a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* That have a known risk to prolong the QT interval or induce torsades de pointes\r\n* Herbal preparations/medications, dietary supplements not prescribed by a medical doctor (MD)
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug (for details):\r\n* Known strong inducers or inhibitors of CYPA/ including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* Those have a narrow therapeutic window and are predominantly metabolized through CYPA\r\n* Those have a known strong risk to prolong the QT interval or induce Torsades de Pointes\r\n* Herbal preparations
Patient is currently receiving any of the following medications and cannot be discontinued =<  days prior to starting study drug: known strong inducers or inhibitors of cytochrome P family , subfamily A, polypeptide / (CYPA/) including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges or that have a narrow therapeutic window and are predominantly metabolized through CYPA/ or herbal preparations/medications or dietary supplements
Known strong inducers or inhibitors of CYPA/, including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges
Received the following agents within  days prior to the first dose of venetoclax: steroid therapy for anti-neoplastic intent; strong and moderate cytochrome P (CYP) A inhibitors or inducers; grapefruit/grapefruit products, seville oranges or star fruit within  days prior to the first dose of venetoclax
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug:\r\n* Known strong inducers or inhibitors of CYPA/, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges\r\n* Those having a narrow therapeutic window and are predominantly metabolized through CYPA/\r\n* Those having a known risk to prolong the QT interval or induce Torsades de Pointes\r\n* Herbal preparations/medications
Patient is currently receiving any of the following medications and cannot be discontinued  days prior to starting study drug: a. Known strong inducers or inhibitors of CYPA/, including grapefruit, grapefruit hybrids, pummelos, star-fruit, and Seville oranges. b. That have a narrow therapeutic window and are predominantly metabolized through CYPA/. c. Herbal preparations/medications, dietary supplements. d. Hormone replacement therapy, topical estrogens (including any intra-vaginal preparations), megestrol acetate and selective estrogen-receptor modulators (e.g. raloxifene).
Consumed grapefruit or grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within  days prior to the first dose of study treatment
Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within  days prior to the initiation of study treatment.
Consumed grapefruit or grapefruit products, seville oranges (including marmalade containing seville oranges), or star fruit within  days prior to the first dose of study treatment
Patients using Seville orange, star fruit, grapefruit and their juices, and St. John's Wort
Actual or potential cytochrome P (CYP) A interactions including: requirement for warfarin; use of strong and moderate CYPA inhibitors or inducers within  days prior to first dose of venetoclax; or consumption of grapefruit, Seville oranges, or star fruit within  days prior to first dose of venetoclax
Patients who are currently receiving or consuming\r\n* Medications that are known strong inducers or inhibitors of cytochrome P, family , subfamily A, polypeptide  (CYPA) =<  days of starting study treatment\r\n Medications with a known risk of prolonging the QT interval or inducing Torsades de Pointes =<  days prior to start of study treatment\r\n* Amiodarone =<  days prior to start of study treatment\r\n* Grapefruit, grapefruit juice, pomegranates, star fruits, Seville oranges or products =<  days prior to start of study treatment\r\n* Warfarin (or derivatives)
Seville oranges within  days before the first dose of study drugs and during the study.
Food or beverages containing grapefruit, Seville oranges, or Star fruit within  days before the first dose of study drugs. Note that food and beverages containing grapefruit, Seville orange, or Star fruit are not permitted during the study.
